Joseph Monahan - 01 Feb 2024 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role: Chief Scientific Officer
Signature: /s/ Mark Ballantyne, Attorney-in-Fact
Issuer symbol: ACRS
Transactions as of: 01 Feb 2024
Net transactions value: -$3,100
Form type: 4
Filing time: 05 Feb 2024, 19:31:24 UTC
Previous filing: 25 Oct 2023
Next filing: 05 Mar 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACRS	Common Stock	Options Exercise		+7,500	+5.8%		137,224	01 Feb 2024	Direct	F1
transaction	ACRS	Common Stock	Tax liability	$3,100	-2,583	-1.9%	$1.20	134,641	01 Feb 2024	Direct	F2
holding	ACRS	Common Stock						193	01 Feb 2024	By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACRS	Restricted Stock Unit	Options Exercise	$0	-7,500	-25%	$0.000000	22,500	01 Feb 2024	Common Stock	7,500		Direct	F1, F3
transaction	ACRS	Employee Stock Option (Right to Buy)	Award	$0	+206,500		$0.000000	206,500	01 Feb 2024	Common Stock	206,500	$1.20	Direct	F4
transaction	ACRS	Restricted Stock Units	Award	$0	+59,000		$0.000000	59,000	01 Feb 2024	Common Stock	59,000		Direct	F1, F5
transaction	ACRS	Restricted Stock Units	Award	$0	+147,500		$0.000000	147,500	01 Feb 2024	Common Stock	147,500		Direct	F1, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2	The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
F3	The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
F4	Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
F5	The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
F6	50% of the shares underlying these restricted stock units vest on each of December 31, 2024 and December 31, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.